Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Merck
Johnson and Johnson
Moodys
Dow

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR ALDARA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Aldara

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00079300 ↗ Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer Completed National Naval Medical Center Phase 1 2004-01-01 RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating patients with basal cell skin cancer.
NCT00142454 ↗ NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) Completed American Society of Clinical Oncology Phase 1 2005-08-24 This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity of treatment.
NCT00142454 ↗ NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) Completed Cancer Research Institute (CRI) Phase 1 2005-08-24 This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity of treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aldara

Condition Name

Condition Name for Aldara
Intervention Trials
Actinic Keratosis 8
Cervical Intraepithelial Neoplasia 3
Actinic Keratoses 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aldara
Intervention Trials
Keratosis, Actinic 12
Keratosis 12
Carcinoma in Situ 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aldara

Trials by Country

Trials by Country for Aldara
Location Trials
United States 133
Germany 11
Austria 8
Australia 5
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aldara
Location Trials
Florida 12
California 9
New York 9
Texas 8
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aldara

Clinical Trial Phase

Clinical Trial Phase for Aldara
Clinical Trial Phase Trials
Phase 4 10
Phase 3 17
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aldara
Clinical Trial Phase Trials
Completed 38
Recruiting 8
Active, not recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aldara

Sponsor Name

Sponsor Name for Aldara
Sponsor Trials
National Cancer Institute (NCI) 10
Graceway Pharmaceuticals, LLC 5
MEDA Pharma GmbH & Co. KG 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aldara
Sponsor Trials
Other 89
Industry 27
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
McKinsey
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.